Precision Psychiatry Market Report 2026

The precision psychiatry market size has grown rapidly in recent years. It will grow from $4.99 billion in 2025 to $5.72 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increasing prevalence of mental health disorders, growing limitations of trial-and-error prescribing, expansion of psychiatric research initiatives, rising availability of neuroimaging technologies, early adoption of pharmacogenomics in psychiatry.

The precision psychiatry market size is expected to see rapid growth in the next few years. It will grow to $9.81 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to increasing investments in precision medicine platforms, rising adoption of ai-enabled diagnostics, expansion of digital mental health solutions, growing demand for personalized psychiatric care, increasing focus on preventive mental health strategies. Major trends in the forecast period include increasing adoption of biomarker-guided treatment pathways, rising use of digital phenotyping tools, growing integration of genetic and neuroimaging data, expansion of AI-driven clinical decision support, enhanced focus on personalized mental health monitoring.

The increasing prevalence of mental health disorders is expected to drive the growth of the precision psychiatry market in the coming years. Mental health disorders include a wide range of conditions, such as depression, anxiety, and bipolar disorder, which affect mood, thinking, and behavior. These disorders are rising as more individuals experience psychological distress due to social, economic, and environmental pressures, coupled with improved screening and public awareness that lead to higher diagnosis rates. Precision psychiatry addresses mental health disorders by enabling data-driven, personalized treatment strategies that improve diagnostic accuracy and therapeutic outcomes. For example, in November 2023, NHS England reported that the rate of probable mental disorders among individuals aged 20 to 23 increased from 18.7% in 2022 to 21.6% in 2023. Consequently, the rising prevalence of mental health disorders is fueling the growth of the precision psychiatry market.

Major companies in the precision psychiatry market are developing innovative therapies, such as prescription digital therapeutics, to provide personalized, data-driven treatment for psychiatric conditions. Prescription digital therapeutics are clinician-prescribed, software-based interventions that deliver evidence-based behavioral therapy modules via mobile devices to improve symptom management and treatment adherence. For instance, in August 2024, Otsuka Precision Health Inc., a US-based precision health subsidiary of Otsuka Holdings, in partnership with Click Therapeutics Inc., launched Rejoyn, the first prescription digital therapeutic cleared by the US FDA for adjunctive treatment of major depressive disorder (MDD) symptoms. Rejoyn delivers a six-week cognitive-emotional training program combining emotional faces memory tasks with cognitive behavioral therapy (CBT)-based skill modules, supporting digital prescribing, patient engagement, and remote monitoring. Its launch highlights how digital therapeutics can complement pharmacological treatments, enabling personalized care and broader adoption of software-based interventions that leverage real-time patient data to optimize outcomes and adherence.

In January 2025, Johnson & Johnson, a US-based pharmaceutical company, acquired Intra-Cellular Therapies Inc. for approximately $14.6 billion. This acquisition aims to expand Johnson & Johnson’s portfolio of innovative psychiatric therapeutics and utilize Intra-Cellular’s expertise in mechanism-based drug development for central nervous system disorders. Intra-Cellular Therapies Inc. is a US-based company focused on developing targeted neuropsychiatric therapies in line with the principles of precision psychiatry.

Major companies operating in the precision psychiatry market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Otsuka Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Illumina Inc., ARUP Laboratories Inc., Sumitomo Dainippon Pharma Company Limited, QIAGEN N.V., Neurocrine Biosciences Inc., Tempus Labs Inc., Myriad Genetics Inc., MedGenome Labs Ltd., Genomind Inc.

North America was the largest region in the precision psychiatry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision psychiatry market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the precision psychiatry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the precision psychiatry market by increasing costs of imported genetic testing kits, neuroimaging equipment, wearable sensors, and advanced analytics hardware used in diagnosis and monitoring. Healthcare providers and research institutions in North America and Europe are most affected due to reliance on specialized imported technologies, while Asia-Pacific faces higher costs for advanced diagnostic infrastructure. These tariffs are increasing implementation costs and slowing technology deployment in clinical settings. However, they are also encouraging domestic development of diagnostic tools, local manufacturing of digital health devices, and regional innovation in cost-optimized precision psychiatry solutions.

The precision psychiatry market research report is one of a series of new reports that provides precision psychiatry market statistics, including precision psychiatry industry global market size, regional shares, competitors with a precision psychiatry market share, detailed precision psychiatry market segments, market trends and opportunities, and any further data you may need to thrive in the precision psychiatry industry. This precision psychiatry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Precision psychiatry is a data-driven approach that integrates genetic, neurobiological, behavioral, and environmental information to understand individual disease mechanisms. Its main goal is to enhance diagnostic accuracy, guide personalized treatments, and improve outcomes by minimizing trial-and-error prescribing. It also supports preventive strategies through personalized risk assessment and ongoing monitoring.

The primary therapeutic approaches in precision psychiatry include pharmacotherapy, psychotherapy, neurostimulation, digital therapeutics, and combination therapies. Pharmacotherapy in precision psychiatry involves personalized medication strategies tailored to an individual’s genetic, biochemical, and clinical profile for treating mental health disorders. It employs technologies such as genetic testing, biomarker analysis, brain imaging, wearable devices, and artificial intelligence and machine learning solutions. It is used for conditions including depression, anxiety disorders, bipolar disorder, schizophrenia, and post-traumatic stress disorder (PTSD). Applications include diagnosis, treatment, and research, serving end users such as clinics, hospitals, research institutes, pharmaceutical companies, and home care settings.

The precision psychiatry market includes revenues earned by entities through psychiatric assessment, personalized treatment planning, remote monitoring, data analytics, and clinical decision support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.